Quoin Pharmaceuticals (QNRX) Projected to Announce Quarterly Earnings on Thursday

Quoin Pharmaceuticals (NASDAQ:QNRX) is expected to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($1.61) per share for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 12:30 PM ET.

Quoin Pharmaceuticals (NASDAQ:QNRX) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.77) EPS for the quarter, beating the consensus estimate of ($2.17) by $0.40.

Quoin Pharmaceuticals Price Performance

Shares of Quoin Pharmaceuticals stock opened at $4.35 on Wednesday. The firm has a 50 day simple moving average of $4.48 and a 200 day simple moving average of $6.37. Quoin Pharmaceuticals has a fifty-two week low of $3.25 and a fifty-two week high of $41.80. The firm has a market cap of $8.74 million, a P/E ratio of -0.15 and a beta of 1.50.

Hedge Funds Weigh In On Quoin Pharmaceuticals

Several large investors have recently bought and sold shares of QNRX. ADAR1 Capital Management LLC acquired a new stake in Quoin Pharmaceuticals during the 4th quarter worth $840,000. Boothbay Fund Management LLC bought a new stake in shares of Quoin Pharmaceuticals during the 4th quarter valued at $863,000. SummitTX Capital L.P. acquired a new position in shares of Quoin Pharmaceuticals in the 4th quarter valued at $935,000. Millennium Management LLC acquired a new position in shares of Quoin Pharmaceuticals in the 4th quarter valued at $1,080,000. Finally, Ikarian Capital LLC bought a new position in shares of Quoin Pharmaceuticals in the 4th quarter worth $3,052,000. 8.63% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on QNRX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research report on Monday, July 20th. ThinkEquity began coverage on Quoin Pharmaceuticals in a research report on Monday, June 15th. They set a “buy” rating for the company. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.